What is the Appropriate Dose of Tolvaptan in ADPKD?

Neera K Dahl¹, Vicente E Torres¹

Affiliations

PMID: 38765581
PMCID: PMC11101796
DOI: 10.1016/j.ekir.2024.01.049

Editorial

What is the Appropriate Dose of Tolvaptan in ADPKD?

Neera K Dahl et al. Kidney Int Rep. 2024.

. 2024 Feb 1;9(4):737-739.

doi: 10.1016/j.ekir.2024.01.049. eCollection 2024 Apr.

Authors

Neera K Dahl¹, Vicente E Torres¹

Affiliation

¹ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 38765581
PMCID: PMC11101796
DOI: 10.1016/j.ekir.2024.01.049

No abstract available

PubMed Disclaimer

Comment on

doi: 10.1016/j.ekir.2024.01.020

Cited by

Spot Versus 24-Hour Urine Osmolality Measurement in Autosomal Dominant Polycystic Kidney Disease: A Diagnostic Test Study.
Akbari A, Sriperumbuduri S, Mangalgi S, Joshi V, Sood M, Buh A, Biyani M, McCudden C, Hundemer GL, Brown PA. Akbari A, et al. Kidney Med. 2025 Jan 15;7(3):100965. doi: 10.1016/j.xkme.2025.100965. eCollection 2025 Mar. Kidney Med. 2025. PMID: 39980937 Free PMC article.
A Primer for Utilizing Deep Learning and Abdominal MRI Imaging Features to Monitor Autosomal Dominant Polycystic Kidney Disease Progression.
Zhu C, He X, Blumenfeld JD, Hu Z, Dev H, Sattar U, Bazojoo V, Sharbatdaran A, Aspal M, Romano D, Teichman K, Ng He HY, Wang Y, Soto Figueroa A, Weiss E, Prince AG, Chevalier JM, Shimonov D, Moghadam MC, Sabuncu M, Prince MR. Zhu C, et al. Biomedicines. 2024 May 20;12(5):1133. doi: 10.3390/biomedicines12051133. Biomedicines. 2024. PMID: 38791095 Free PMC article. Review.
Response to the Letter to the Editor Entitled "Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes".
Dahl NK, Torres VE. Dahl NK, et al. Kidney Int Rep. 2025 May 28;10(8):2880. doi: 10.1016/j.ekir.2025.05.040. eCollection 2025 Aug. Kidney Int Rep. 2025. PMID: 40814628 Free PMC article. No abstract available.
Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes.
De Rosa LI, Catania M, Kola K, Paolisi M, Bianca P, Manunta P, Vezzoli G, Sciarrone Alibrandi MT. De Rosa LI, et al. Kidney Int Rep. 2025 May 27;10(8):2879. doi: 10.1016/j.ekir.2025.03.059. eCollection 2025 Aug. Kidney Int Rep. 2025. PMID: 40814604 Free PMC article. No abstract available.
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD.
Geertsema P, Soonawala D, Gansevoort RT, Meijer E. Geertsema P, et al. Kidney Int Rep. 2024 Nov 12;10(1):271. doi: 10.1016/j.ekir.2024.10.042. eCollection 2025 Jan. Kidney Int Rep. 2024. PMID: 39810775 Free PMC article. No abstract available.

References

1. Bhatt P.R., McNeely E.B., Lin T.E., Adams K.F., Patterson J.H. Review of Tolvaptan's pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med. 2014;3:1276–1290. doi: 10.3390/jcm3041276. - DOI - PMC - PubMed
1. Shoaf S.E., Chapman A.B., Torres V.E., Ouyang J., Czerwiec F.S. Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol. 2017;57:906–917. doi: 10.1002/jcph.880. - DOI - PMC - PubMed
1. Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418. doi: 10.1056/NEJMoa1205511. - DOI - PMC - PubMed
1. Todorova P., Arjune S., Hendrix C., et al. Interaction between determinants governing urine volume in patients with ADPKD on tolvaptan and its impact on quality of life. Kidney Int Rep. 2023;8:1616–1626. doi: 10.1016/j.ekir.2023.05.011. - DOI - PMC - PubMed
1. Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–1942. doi: 10.1056/NEJMoa1710030. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

What is the Appropriate Dose of Tolvaptan in ADPKD?

Affiliation

What is the Appropriate Dose of Tolvaptan in ADPKD?

Authors

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources